SSG
SYRE icon

Summit Securities Group’s Spyre Therapeutics SYRE Stock Holding History

Summit Securities Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-562
Closed -$28.3K – 1364
2026
Q1 		$28.3K Buy
+562
New +$21.2K ﹤0.01% 471
2025
Q2 		– Sell
-133
Closed -$2.15K – 1421
2025
Q1 		$2.15K Buy
+133
New +$2.77K ﹤0.01% 667

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Summit Securities Group's SYRE Position: Q2 2026 in Review

Summit Securities Group sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 562 shares — an estimated $28.3K sold.

Summit Securities Group first reported a position in SYRE in Q1 2025 and held it in 2 quarters. The position peaked at $28.3K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Summit Securities Group reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 562 Spyre Therapeutics shares in Q2 2026, an estimated $28.3K.
  • Summit Securities Group first reported a position in Spyre Therapeutics in Q1 2025 and held it in 2 quarters.
  • Summit Securities Group's Spyre Therapeutics position peaked at $28.3K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.